| Overview |
| bsm-60904m-100ul |
| CD80 Monoclonal Antibody |
| IHC |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| KLH conjugated synthetic peptide derived from human CD80 |
| Monoclonal |
| 13A5 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 941 |
| P33681 |
| Cell membrane |
| Activation B7-1 antigen; B lymphocyte activation antigen B7; B7; B7-1; B7-1 antigen; BB1; CD28 antigen ligand 1; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); CD80 antigen; CD80 molecule; CD80_HUMAN; Costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; LAB7; T-lymphocyte activation antigen CD80. |
| CD80 is a member of the Ig superfamily and serves as the ligand for two T cell molecules, CD28 and CTLA4. Interactions between CD28 and CD80 on activated B cells result in enhanced T cell activation. CD80 is rapidly induced on the surface of in vitro activated B cells, Epstein Barr Virus (EBV) transformed B cell lines, Burkitts lymphoma cell lines, freshly isolated follicular B lymphoma cells, T cells, and monocytes. It is also expressed at high levels in dendritic cells. It reacts weakly with a small proportion of non activated normal B cells and with HTLV1 infected T cells. CD80 does not react with peripheral monocytes, resting and activated normal T cells, T cell lines and T cell clones, nor with myelomonocytic cell lines. |
| Application Dilution |
| IHC |
1:100-500 |
Powered by Bioz